Wednesday February 21st 2018

Protein 4.1R attenuates autoreactivity in experimental autoimmune encephalomyelitis by suppressing CD4(+) T cell activation.

In this study, we investigated the potential role of protein 4.1R in pathologic processes of EAE by using 4.1R knockout mouse model. Our results suggest that 4.1R can prevent pathogenic autoimmunity in MS/EAE progression by suppressing the CD4(+) T cell activation. PMID: 25243644 [PubMed – as supplied by publisher] (Source: Cellular Immunology)

MedWorm Sponsor Message: Find the best Christmas Sales, Boxing Day Sales and January Sales here.

Read this article: 

Protein 4.1R attenuates autoreactivity in experimental autoimmune encephalomyelitis by suppressing CD4(+) T cell activation.

Leave a Comment

More from category

MS patients who feel stigmatized more likely to suffer from depression
MS patients who feel stigmatized more likely to suffer from depression

People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, according to [Read More]

Stigma increases risk of depression for people with Multiple Sclerosis
Stigma increases risk of depression for people with Multiple Sclerosis

(Penn State) People with Multiple Sclerosis -- MS -- who feel stigmatized are more likely to suffer from depression, [Read More]

Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…
Technologies for advanced gait and balance assessments in people with multiple sclerosis – Shanahan CJ, Boonstra FMC, Cofr é Lizama LE, Strik M,…

Subtle gait and balance dysfunction is a precursor to loss of mobility in multiple sclerosis (MS). Biomechanical [Read More]

What side effects can result from interferon?
What side effects can result from interferon?

Interferon is used to treat several health conditions, but it has a range of side effects. We look at how these vary in [Read More]

FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS
FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS

Glatopa 40 mg/mL joins already-approved Glatopa 20 mg/mL, a glatiramer acetate generic for treatment of relapsing forms [Read More]